Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

By | November 30, 2021
In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.